AI1 sumber
Novartis CEO says AI could cut drug development time to eight years
Judul dari Crypto Briefing

Poin penting
- Artificial intelligence integration in the pharmaceutical industry could potentially reduce drug development timelines to eight years, according to the chief executive officer of Novartis.
- Utilizing AI technology is expected to revolutionize drug creation by enhancing operational efficiency and improving success rates.
- However, significant regulatory and policy challenges remain for widespread adoption across the healthcare sector.
Diringkas otomatis oleh Kryptokite dari laporan Crypto Briefing. Baca sumber aslinya untuk detail lengkap. Untuk saat ini berita dan ringkasan masih dalam bahasa Inggris.
Sumber
- Crypto BriefingNovartis CEO says AI could cut drug development time to eight years · 2 jam yang laluBaca di Crypto Briefing
Linimasa berita
- Bitcoinist1 menit baca
ARK Invest Buys $90M in Anthropic Shares While Trimming Ethereum ETF Holdings
- The Defiant1 menit baca
Intel 18A vs. TSMC N2: How to Read the Chip Claims
- Crypto Briefing1 menit baca
Solana adds 1.5% share of tokenized equities trading volume in a year
- Crypto Briefing1 menit baca
Cursor plans to explore phasing out Chinese AI models, reports say
- CryptoSlate1 menit baca
AI data center boom linked to 650 premature US deaths as pollution spreads across states
Bagikan
Kryptokite menautkan ke berita aslinya dan tidak pernah menerbitkan ulang artikel lengkap. Ringkasan dibuat otomatis dan bisa mengandung kesalahan; tidak ada di sini yang merupakan nasihat keuangan.